Follow
Carol Pollock
Carol Pollock
Professor of Medicine University of Sydney
Verified email at sydney.edu.au
Title
Cited by
Cited by
Year
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
ADVANCE Collaborative Group
New England journal of medicine 358 (24), 2560-2572, 2008
97722008
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ...
New England journal of medicine 380 (24), 2295-2306, 2019
48962019
A randomized, controlled trial of early versus late initiation of dialysis
BA Cooper, P Branley, L Bulfone, JF Collins, JC Craig, MB Fraenkel, ...
New England Journal of Medicine 363 (7), 609-619, 2010
10162010
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
A Levin, M Tonelli, J Bonventre, J Coresh, JA Donner, AB Fogo, CS Fox, ...
The Lancet 390 (10105), 1888-1917, 2017
8962017
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ...
The Lancet 393 (10184), 1937-1947, 2019
4842019
Glucose handling by the kidney
A Mather, C Pollock
Kidney international 79, S1-S6, 2011
4262011
The influence of dialysis treatment modality on the decline of remaining renal function
MJ Lysaght, EF Vonesh, F Gotch, L Ibels, M Keen, B Lindholm, KD Nolph, ...
Asaio Journal 37 (4), 598-604, 1991
4261991
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
Sharp Collaborative Group
American heart journal 160 (5), 785-794. e10, 2010
4082010
Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy?
U Panchapakesan, K Pegg, S Gross, MG Komala, H Mudaliar, J Forbes, ...
PloS one 8 (2), e54442, 2013
3332013
Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
CT Chan, PJ Blankestijn, LM Dember, M Gallieni, DCH Harris, CE Lok, ...
Kidney international 96 (1), 37-47, 2019
3212019
Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis
ISPD Adequacy of Peritoneal Dialysis Working Group
Peritoneal dialysis international 26 (5), 520-522, 2006
2632006
Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups: results …
KW Mahaffey, MJ Jardine, S Bompoint, CP Cannon, B Neal, ...
Circulation 140 (9), 739-750, 2019
2622019
Developing a set of core outcomes for trials in hemodialysis: an international Delphi survey
N Evangelidis, A Tong, B Manns, B Hemmelgarn, DC Wheeler, P Tugwell, ...
American Journal of Kidney Diseases 70 (4), 464-475, 2017
2592017
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes”(KDIGO) Controversies Conference
IC Macdougall, AJ Bircher, KU Eckardt, GT Obrador, CA Pollock, ...
Kidney international 89 (1), 28-39, 2016
2472016
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics
MJ Jardine, KW Mahaffey, B Neal, R Agarwal, GL Bakris, BM Brenner, ...
American journal of nephrology 46 (6), 462-472, 2018
2402018
Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD
BA Cooper, EL Penne, LH Bartlett, CA Pollock
American Journal of Kidney Diseases 43 (1), 61-66, 2004
2392004
Validity of subjective global assessment as a nutritional marker in end-stage renal disease
BA Cooper, LH Bartlett, A Aslani, BJ Allen, LS Ibels, CA Pollock
American journal of kidney diseases 40 (1), 126-132, 2002
2162002
Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial
GS Doig, F Simpson, R Bellomo, PT Heighes, EA Sweetman, D Chesher, ...
Intensive care medicine 41, 1197-1208, 2015
1962015
Erythropoiesis‐stimulating agent hyporesponsiveness
DW Johnson, CA Pollock, IC Macdougall
Nephrology 12 (4), 321-330, 2007
1952007
Integrated actions of transforming growth factor-β1 and connective tissue growth factor in renal fibrosis
W Qi, S Twigg, X Chen, TS Polhill, P Poronnik, RE Gilbert, CA Pollock
American Journal of Physiology-Renal Physiology 288 (4), F800-F809, 2005
1902005
The system can't perform the operation now. Try again later.
Articles 1–20